Rifapentine

Essential medicine status ✓

EMLc | ATC codes: J04AB05

Indication	Latent tuberculosis ICD11 code: 1B14
INN	Rifapentine
Medicine type	Chemical agent
List type	Core
Formulations	**Oral > Solid > dispersible tablet:** 150 mg (EMLc) **Oral > Solid > tablet:** 150 mg ; 300 mg
EML status history	First added in 2015 (TRS 994) Changed in 2021 (TRS 1035) Changed in 2025 (TRS 1064)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Wikipedia	Rifapentine
DrugBank	Rifapentine

Summary of evidence and Expert Committee recommendations

The Expert Committee recognized that age-appropriate, child-friendly formulations of medicines for the treatment of tuberculosis, when available and quality-assured, are essential public health interventions to meet the needs of paediatric patients. The Committee noted that currently listed rifapentine formulations for tuberculosis preventive treatment on the EMLc are 150 mg and 300 mg conventional tablets, which may not be acceptable for paediatric patients unable to swallow solid dosage forms. The 150 mg dispersible tablet rifapentine formulation is prequalified by WHO and is available through the Stop TB Partnership global drug facility. Based on these considerations, the Expert Committee recommended the addition of rifapentine 150 mg dispersible tablets to the core list of the EMLc for tuberculosis preventive treatment in accordance with recommendations in WHO guidelines.